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SUMMARY
The induction of tumor suppressor proteins capable
of cancer cell apoptosis represents an attractive
option for the re-purposing of existing drugs. We
report that the anti-malarial drug, chloroquine (CQ),
is a robust inducer of Par-4 secretion from normal
cells in mice and cancer patients in a clinical
trial. CQ-inducible Par-4 secretion triggers paracrine
apoptosis of cancer cells and also inhibits metastatic
tumor growth. CQ induces Par-4 secretion via the
classical secretory pathway that requires the activa-
tion of p53. Mechanistically, p53 directly induces
Rab8b, a GTPase essential for vesicle transport of
Par-4 to the plasma membrane prior to secretion.
Our findings indicate that CQ induces p53- and
Rab8b-dependent Par-4 secretion from normal cells
for Par-4-dependent inhibition of metastatic tumor
growth.
INTRODUCTION
Among the tumor suppressor proteins expressed ubiquitously
by normal cells and tissues, Prostate apoptosis response-4
(Par-4, also known as PAWR) exhibited both intracellular and
extracellular pro-apoptotic functions (Hebbar et al., 2012).
Studies in cell culture and mouse models indicated that Par-4
selectively induced apoptosis in diverse cancer cells but not in
normal cells (Hebbar et al., 2012). Consistent with this finding,
transgenic mice overexpressing Par-4 resisted the growth of tu-
mors (Zhao et al., 2007). We and others have shown that inacti-
vation, downregulation, or mutation of Par-4 has occurred in
several types of cancers (Hebbar et al., 2012). Par-4 secreted
by normal and cancer cells bound selectively to a receptor
GRP78 on the cancer cell surface, where it induced apoptosis
by a caspase-8/caspase-3-dependent pathway (Burikhanov
et al., 2009). In contrast to cancer cells, normal cells expressed
low-to-undetectable levels of basal or inducible GRP78 at the
cell surface and resisted apoptosis by extracellular Par-4 (Buri-
khanov et al., 2009).
Par-4 null mice developed spontaneous, as well as inducible,
tumors at a higher frequency than that seen in wild-type
(Par-4+/+) mice (Garcı́a-Cao et al., 2005), an outcome that
implied that basal levels of Par-4 were effective in regulating tu-
mor growth. Elevation of extracellular Par-4 in cell-culture condi-
tioned medium (CM) induced apoptosis of cancer cell cultures
(Burikhanov et al., 2009, 2013, 2014a, 2014b), and systemic
elevation of Par-4 in mice inhibited growth of tumors (Zhao
et al., 2011). Using a chemical biology approach to elevate the
secretion of Par-4 from normal cells, we identified a 3-arylquino-
line, Arylquin-1, as a potent Par-4 secretagogue in normal cell
cultures and mouse models (Burikhanov et al., 2014b). The
secreted Par-4, which was produced by the administration of
Arylquin-1, induced the paracrine apoptosis of diverse cancer
cells (Burikhanov et al., 2014b). To identify other compounds
that functioned as Par-4 secretagogues, we tested a panel of
FDA (Food and Drug Administration)-approved generic drugs
for Par-4 secretion from normal cells. This screening process
identified the antimalarial drug chloroquine (CQ) as a potent
inducer of Par-4 secretion from normal cells under conditions
that showed no normal cell death.
In clinical trials, CQ also showed encouraging results in sub-
sets of diverse cancers (Rebecca and Amaravadi, 2016). CQ
induced cytotoxic effects in tumors by blocking autophagy,
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but in mice containing oncogenic K-ras and lacking functional
p53, loss of autophagy accelerated tumor progression (Rose-
nfeldt et al., 2013). CQ has been reported to display pleiotropic
mechanisms of action that include inhibition of autophagy by
blocking the fusion of the autophagosome with the lysosome
(Boya et al., 2003), lethal lysosomal destabilization (Maycotte
et al., 2012), and normalization of tumor vasculature (Maes
et al., 2014). Absent from this list, however, was any report of
the induction of protein secretion by CQ. The findings reported
here suggested that CQ induced Par-4 secretion from normal
cells by a mechanism that was dependent on tumor suppressor
p53 and its transcriptional target, Rab8b, and that Par-4 was
essential for paracrine apoptosis of p53-deficient cancer cells
and tumor growth inhibition by CQ. Moreover, CQ-induced
secretion of Par-4 was prevented by brefeldin A (BFA), which
blocked the conventional pathway but not the non-conventional
pathways (Klausner et al., 1992; Grieve and Rabouille, 2011).
Loss of Rab8a, which was involved in autophagic secretion
(Dupont et al., 2011), did not prevent the induction of Par-4
secretion by CQ. This finding indicated that Par-4 secretion
occurred independently of the non-conventional autophagic
pathway.
RESULTS
CQ Induced Robust Par-4 Secretion from Normal Cells
To test FDA-approved generic drugs for induction of Par-4
secretion, we used a panel of 17 structurally related drugs
containing either quinoline or quinolone pharmacophores (Table
S1). Mouse embryonic fibroblasts (MEFs) with low (i.e., 4–5)
passages were treated with the compounds or vehicle, and
Par-4 secretion in the CM was determined by western blot anal-
ysis. CQ and hydroxychloroquine (HCQ) induced robust secre-
tion of Par-4 (Figure S1A). To confirm the findings of this initial
screen, normal mouse and human cell lines were treated with
various concentrations of either CQ or vehicle for 24 hr, and
their CM was examined for secreted Par-4. CQ caused dose-
dependent secretion of Par-4 in the CM from wild-type
(p53+/+) MEFs, as well as from normal human prostate stromal
cells (PrSCs) and epithelial cells (PrECs) and from normal hu-
man lung fibroblast (HEL) cells and epithelial cells (HBECs)
(Figure 1A).
CQ blocked autophagic degradation of proteins by preventing
the fusion of the autophagosome with the lysosome (Mariño
et al., 2014), and we confirmed that CQ functioned as expected
and caused the accumulation of LC-3II and p62 (Figure S1B).
However, the process of preventing autophagy may trigger
caspase activation and apoptosis (Amaravadi et al., 2007). We,
therefore, determined whether CQ-induced secretion of Par-4
occurred by an apoptosis-independent process. Wild-type
MEF cells were pretreated with the pan-caspase inhibitor
zVAD-fmk, which blocked caspase-dependent apoptosis, and
then were further treated with either CQ or vehicle. As seen in
Figure S1B, CQ-induced secretion of Par-4 was not inhibited
by zVAD-fmk, a finding that indicated that CQ-induced Par-4
secretion was not associated with apoptosis of the cells. Normal
cells did not undergo cell-cycle arrest or growth inhibition when
treated with CQ (Figure S1B). Moreover, there was no difference
in p62/SQSTM1 levels between the Par-4+/+ and Par-4/ cells
at basal level and after CQ treatment (Figure S1B), implying
that Par-4 does not affect autophagy.
We next determined whether CQ induced Par-4 secretion in
cancer cells. Lung cancer cells or prostate cancer cells were
treated with CQ, and their CMwas examined for Par-4 secretion.
Figure 1. CQ Induced Secretion of Par-4
(A) CQ induced Par-4 secretion in normal cells.
Various normal cell lines were treated with the
indicated amounts of chloroquine (CQ) or vehicle
(V) control for 24 hr. The conditioned medium (CM)
and whole-cell lysates were subjected to western
blot analysis with the indicated antibodies. We
used Collagen1A1 (Col1A1) as loading control for
protein secretion and/or albumin levels in plasma
as control for CM. Actin served as a loading
control for the lysates. PrSC, normal human pros-
tate stromal cells; PrEC, normal human prostate
epithelial cells.
(B) CQ induced systemic secretion of Par-4 in mice
and patients. (Left) C57BL/6micewere injected i.p.
with a single dose (50 mg/kg body weight) of CQ,
and plasma samples were collected after 24 hr
and processed by western blot analysis. Data are
representative of four mice. (Right) RCC patients
were treated with HCQ (400 mg/day) pre-opera-
tively for 2 weeks in a CQ clinical trial at the Uni-
versity of Pittsburgh. Pre- and post-treatment
plasma (Pre and Post, respectively) were sub-
jected to western blot analysis. Fold increase in
post-treatment Par-4 levels relative to the corre-
sponding pre-treatment levels is shown.
See also Figure S1.
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In contrast to its effects in normal cells, as noted earlier, CQ
failed to induce Par-4 secretion in prostate cancer cells (LNCaP,
C4-2B, DU145, and PC-3) and in lung cancer cells (H460 and
A549) (Figure S1C). To ascertain the physiological relevance
of these findings, immunocompetent mice were treated with a
single injection of CQ or control vehicle, and, after 24 hr, their
plasma samples were tested for systemic levels of Par-4. Rela-
tive to vehicle treatment, CQ induced the robust elevation of
Par-4 in mouse plasma (Figure 1B). In addition, plasma samples
from renal cell carcinoma (RCC) patients—whowere taking HCQ
prior to surgery in a clinical trial to test the efficacy of repurposing
CQ as a single agent against cancer (http://www.clinicaltrials.
gov/ct2/show/NCT01144169?term=hydroxychloroquine&rank=
10)—showed elevated levels of Par-4 relative to pre-treatment
levels (Figure 1B).
Induction of Par-4 Secretion from Normal Cells by CQ
Caused Paracrine Apoptosis in Cancer Cells
To determine the biological significance of Par-4 secreted in
response to CQ, we tested co-cultures of MEFs and various
p53-deficient or p53 wild-type cancer cell lines for apoptosis
with CQ or vehicle. The p53-deficient lung cancer cells (H1299,
HOP92, and KP7B), as well as the p53-deficient prostate cancer
cells (PC-3), and the wild-type p53-expressing lung cancer
cells (H460) were sensitive to apoptosis when co-cultured with
Par-4+/+ MEFs and treated with CQ (Figure 2A). These cells
were not sensitive to apoptosis when co-cultured with Par-4/
MEFs and treated with CQ (Figure 2A). The DU145 (p53-defi-
cient) prostate cancer cells or A549 (p53 wild-type) lung cancer
cells, which were resistant to apoptosis by Par-4 (Burikhanov
et al., 2009, 2013), were also resistant to apoptosis by the
Figure 2. CQ Induced Paracrine Apoptosis of Cancer Cells via Induction of Par-4 Secretion from Normal Cells
(A) CQ induced paracrine apoptosis in cancer cells. Par-4+/+ or Par-4/ MEFs were co-cultured with various cancer cells or normal cells and treated with CQ or
vehicle. After 24 hr, the cells were scored for apoptosis.
(B) CQ induced paracrine apoptosis in cancer cells by a Par-4-dependent mechanism. Aliquots of CM from wild-type MEFs treated with CQ (20 mM) were
incubated with control (C) antibody (Ab), Par-4 (P) Ab, or GRP78 (G) Ab and then transferred to H460 cells. After 24 hr, the cells were scored for apoptosis. V,
vehicle.
(C) Plasma from CQ-treated mice induced apoptosis in cancer cells by a Par-4- and GRP78-dependent mechanism. Plasma from C57BL/6 mice injected with
vehicle (V) or CQ was tested for ex vivo apoptosis in H460 cells in the presence of control (C) antibody (Ab), Par-4 (P) Ab, or GRP78 (G) Ab. The cells were scored
for apoptosis.
(D) Plasma from CQ-treated patients induced apoptosis in cancer cells by a Par-4- and GRP78-dependent mechanism. Aliquots of RCC4 patient plasma were
incubated with control (C) antibody (Ab), Par-4 (P) Ab, or GRP78 (G) Ab and then applied to H460 cells. Apoptotic cells were scored after 24 hr.
Error bars indicate mean of at least three independent experiments ± SD. *p < 0.0001, by Student’s t test. See also Figure S2.
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Par-4 secreted from CQ-treated Par-4+/+ MEFs in experiments
that served as internal controls (Figure 2A). Cancer cell apoptosis
was also induced by the CM of Par-4+/+ MEFs treated with CQ
(Figure 2B). The apoptotic activity of the CM was inhibited by
the Par-4 antibody, which neutralized the Par-4 in the CM, or
by the GRP78 antibody, which inhibited the binding of Par-4 to
its receptor GRP78 on the cancer cell surface (Figure 2B). The
A549 cells treated with the nuclear factor kB (NF-kB) inhibitor
PS-1145, which elevated the Par-4 receptor GRP78 on the
cancer cell surface (Burikhanov et al., 2013), were sensitized to
apoptosis by the Par-4 secreted in the CM from MEFs in
response to CQ treatment (Figure S2A).
The plasma frommice treatedwith a single dose of CQ, but not
the plasma from control vehicle-treated mice (shown in Fig-
ure 1B), also induced ex vivo apoptosis of cancer cells. This ac-
tivity was, again, neutralized either by the Par-4 antibody or by
the GRP78 antibody (Figure 2C). Moreover, the plasma from pa-
tient RCC4 showed an induction of Par-4, of ca. 3-fold, following
CQ treatment (shown in Figure 1B). Cancer cells (PC-3, H460,
HOP92, and H1299) underwent apoptosis with aliquots of
post-CQ treatment RCC4 plasma relative to the background
level apoptosis produced by aliquots of pre-CQ-treatment
plasma (Figure S2B). Importantly, apoptosis of cancer cells by
post-CQ treatment plasma from RCC4 was neutralized by the
Par-4 or GRP78 antibody (Figure 2D). Taken together, these find-
ings indicated that CQ-induced Par-4 expression levels in either
the CM of cell cultures or in the plasma of CQ-treated mice and
humans were adequate to trigger apoptosis of cancer cells.
CQ Induced Paracrine Apoptosis and Tumor Growth
Inhibition by Par-4-Dependent Mechanism
We previously established that systemic elevation of Par-4 in-
hibited the growth of LLC1-derived metastatic lung tumor nod-
ules in syngeneic mice (Zhao et al., 2011). In results similar to
our findings on the paracrine apoptosis of cancer cells induced
by the CM from CQ-treated normal cells (see Figure 2A), we
noted that the CM from CQ-treated Par-4+/+ MEFs, but not
from CQ-treated Par-4/ MEFs induced apoptosis of LLC1
cells. This apoptotic activity in the CM was inhibited by the
Par-4 antibody or GRP78 antibody (Figure S3A). To test whether
CQ inhibited the growth of LLC1-derived tumor nodules in this
model of experimental metastasis, we injected LLC1 cells intra-
venously into Par-4+/+ (wild-type) or Par-4/ mice and then in-
jected CQ (intraperitoneally [i.p.], 25 mg/kg body weight) once
daily for 5 consecutive days. Tumor growth was examined
over a 21-day period. The plasma from CQ-treated Par-4+/+
mice, but not from CQ-treated Par-4/ mice, showed robust
Par-4 secretion relative to the plasma from vehicle-treated
mice (Figure 3A). Luciferase imaging, as well as the scoring of
the tumors in mice treated with vehicle indicated that Par-4/
mice showed a significantly higher number of lung nodules
than the number of nodules in the Par-4+/+ mice (Figure 3A).
CQ induced >50% inhibition of tumor nodules in the lungs of
Par-4+/+ mice but only ca.10% inhibition of tumor nodules in
Par-4/ mice (Figure 3A).
The plasma from CQ-treated Par-4+/+ mice, but not the
plasma from CQ-treated Par-4/ mice, induced ex vivo
apoptosis in LLC1 cells. This activity of the plasma was neutral-
ized by the Par-4 or GRP78 antibody but not by a control anti-
body (Figure 3B). These results suggested that basal levels of
Par-4 in wild-type mice prevented the establishment and growth
of cancer cells and that Par-4 levels elevated in response to CQ
were essential for the further inhibition of lung tumor nodules.
To test directly the role of Par-4 secreted in response to CQ,
we used the Par-4 neutralizing antibody and examined whether
it blocked CQ-induced inhibition of LLC1-derived lung tumor
nodules. Athymic nu/numice were injected with LLC1 cells intra-
venously, and after 24 hr, the mice were injected with vehicle or
CQ (i.p., 25 mg/kg body weight) once daily for 5 consecutive
days. Mice injected with CQ were also injected with either the
Par-4 antibody or immunoglobulin G (IgG) control antibody.
As seen in Figure 3C, relative to vehicle control, CQ induced
>85% inhibition of LLC1 tumor nodules in the lungs of nude
mice in the presence of control IgG, but only ca. 40% inhibition
of lung tumor nodules in the presence of Par-4 antibody. CQ
also inhibited lung metastasis by EO771 breast cancer cells in
Par-4+/+ mice but not in Par-4/ mice (Figure S3B). Importantly,
CQ inhibited lung metastasis by EO771 cells in the presence of
control IgG antibody but not in the presence of Par-4 antibody
(Figure S3B). These results indicated that CQ-inducible secre-
tion of Par-4 plays a significant role in inhibition of lung tumor
nodules in two different experimental metastasis models. By
contrast, yet consistent with the findings of Xia et al. (2014),
CQ failed to inhibit the growth of LLC1- or H460-derived tumor
xenografts in the flanks of mice (Figure S3C). Collectively, these
findings indicated that Par-4 levels secreted by normal cell
cultures and from mice and patients in response to CQ were
adequate to cause ex vivo apoptosis of cancer cells and to inhibit
the growth of metastatic lung tumor nodules in mice.
Induction of Par-4 Secretion by CQ Required
Components of the Classical Secretory Pathway
We reported previously that Nutlin-3a activated p53 and pro-
moted Par-4 secretion via the BFA-sensitive classical secretory
pathway involving the transport of proteins from the endoplasmic
reticulum (ER) to the Golgi and onward to the plasma membrane
(Burikhanov et al., 2014a). Importantly, p53 function was essen-
tial for secretion of Par-4 via the classical pathway (Burikhanov
et al., 2014a). As CQ was known to cause activation of p53
through the ATM-signaling pathway (Sohn et al., 2002; Loehberg
et al., 2007;Maclean et al., 2008), we testedwhether p53 function
was required for CQ-induced Par-4 secretion. Wild-type or p53
null MEFs were treated with CQ, Arylquin-1, or Nutlin-3a. As ex-
pected, Nutlin-3a, an inhibitor of MDM2 binding to p53 (Vassilev
et al., 2004), inducedPar-4 secretion in a p53-dependentmanner
(Figure 4A). Similarly, CQ andArylquin-1 caused robust induction
of Par-4 secretion in wild-type MEFs, but not in p53 null MEFs
(Figure 4A). Moreover, CQ induced p53 activation, as judged by
the increase in phospho-S15-p53 and total p53 expression in
wild-typeMEFs (Figure 4B). Activation of p53 by CQwas accom-
panied by increased p53-dependent transcription (Figure S4A)
and upregulation of p53-responsive genes p21 and PIG3 in
MEFs and normal mouse lung tissues (Figures 4B and S4B).
Although CQ caused an increase in total Par-4 protein levels
(see Figures 1 and 4), it did not induce Par-4 at the RNA level (Fig-
ure S4C), implying that Par-4 protein levels were elevated by
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CQ-induced translational/posttranslational regulation. Collec-
tively, these data suggested that p53 was activated by CQ and
that p53 function was required for induction of Par-4 secretion
by CQ but not for elevation of intracellular Par-4 protein levels.
These data are consistent with chromatin immunoprecipiation
(ChIP) data (Figure 6B) and an observation that the Par-4
(PAWR) gene lacks p53 consensus-binding sites for transcrip-
tional regulation by p53 (Burikhanov et al. (2014a).
We previously showed that UACA, an inflammation-associ-
ated protein, bound to Par-4, sequestered it in the ER, and
thereby prevented Par-4 secretion (Burikhanov et al., 2013).
UACA expression was inhibited by p53 but was induced by
NF-kB activation. Activation of p53 or inhibition of NF-kB activa-
tion promoted Par-4 secretion (Burikhanov et al., 2013). Because
CQ activated p53, we tested whether CQ suppressed NF-kB ac-
tivity and UACA expression. Normal and cancer cells were trans-
fected with reporter controls for NF-kB or AP-1 and treated with
CQ or vehicle for 18 hr. CQ inhibited NF-kB activity, but not AP-1
activity, in normal cells (Figure S4D). Moreover, CQ inhibited the
expression of UACA and NF-kB-regulated genes cIAP1 and
XIAP in a p53-dependent manner (Figure 4C), and BFA inhibited
CQ-induced Par-4 secretion (Figure 4D). By contrast, in cancer
cells that failed to show induced Par-4 secretion in response to
CQ (Figure S1C), CQ neither induced p53 nor inhibited NF-kB
activity, and CQ consistently failed to downregulate UACA (Fig-
ures S4D and S5A). Collectively, these studies indicated that,
similar to our findings with Nutlin-3a (Burikhanov et al., 2014a),
CQ induced Par-4 secretion by the classical secretory pathway
that is dependent on UACA suppression by p53 and by inhibition
of NF-kB activity.
Rab8b Is a Target of p53 Critical for Par-4 Secretion
from Normal Cells
UACA suppression was essential for induced secretion of Par-4
in response to Nutlin-3a. UACA suppression by RNAi resulted in
induced secretion of Par-4 only from cells expressing wild-type
p53, but not from cells lacking p53 expression (Burikhanov
et al., 2014a). This finding indicated that p53 function was critical
for Par-4 secretion and that p53 must regulate other compo-
nents of the classical secretory pathway to induce Par-4 secre-
tion. Members of the Rab family of GTPases were essential for
vesicle transport of proteins from the ER to the Golgi and from
Figure 3. CQ Induced Tumor Growth Inhibi-
tion by a Par-4-Dependent Mechanism
(A) CQ induced Par-4 secretion and tumor growth
inhibition. Wild-type (WT or Par-4+/+) or Par-4
knockout (Par-4 KO or Par-4/) C57BL/6 mice
were injected intravenously (i.v.) with LLC1 cells
(expressing luciferase) and, 24 hr later, injected i.p.
with CQ (25mg/kg body weight) or vehicle (V) once
every day for 5 consecutive days. Plasma from
mice was collected 24 hr after the last injection and
subjected to western blot (WB) analysis for Par-4
or Coomassie blue staining for albumin (lower left
panel). Tumor growth in the mice was followed
by fluorescent imaging for luciferase expression
using an IVIS imager, and representative images
are shown (upper left panel). The lungs were
perfused and stained with India ink (upper right
panel), tumor nodules were scored, and percent
growth inhibition with CQ relative to vehicle was
computed (lower right panels). *p < 0.001, by
Student’s t test.
(B) Par-4 in plasma from CQ-treated mice induced
ex vivo apoptosis in LLC1 cells. Aliquots of plasma
from Par-4+/+ or Par-4/ mice treated with CQ or
vehicle (V), tested by western blot analysis in (A),
were incubated with LLC1 cells for 24 hr, and the
cells were scored for apoptosis. Moreover, ali-
quots of plasma from Par-4+/+ mice treated with
CQ were incubated with control antibody (C-Ab),
Par-4 antibody (P-Ab), or GRP78 antibody (G-Ab)
and then transferred to LLC1 cells. After 24 hr, the
cells were scored for apoptosis. *p < 0.0001, by
Student’s t test.
(C) CQ-induced Par-4 secretion is essential for
tumor growth inhibition. Athymic (nu/nu) mice were
injected intravenously (i.v.) with LLC1 cells and,
24 hr later, injected i.p. with CQ (25 mg/kg body
weight) or vehicle once every day for 5 consecutive
days. Animals injected with CQ were also injected with either the control IgG or Par-4 polyclonal antibody (Par-4 Ab) (20 mg per injection). After 21 days, the
lungs were perfused and stained with India ink (upper panel), and the tumor nodules were scored (lower panel).
Error bars indicate mean ± SD. *p = 0.007, by Student’s t test. See also Figure S3.
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the Golgi to the plasma membrane for secretion (Stenmark and
Olkkonen, 2001). Several members of the Rab family contained
putative, p53 consensus-binding sites in their promoter region
(http://www.sabiosciences.com/chipqpcrsearch.php). Because
Par-4 was localized to the apical surface of prostate secretory
luminal cells (Boghaert et al., 1997), and because recent studies
indicated that several Rab proteins were involved in apical trans-
port of proteins (Sobajima et al., 2014; Sato et al., 2014), we
tested whether the expression of Rab genes containing putative
p53-binding sites in their promoter region were essential for
Par-4 secretion. These studies indicated that Rab8b null MEF
cells, but not Rab8a null MEF cells, failed to show induction of
Par-4 secretion by CQ (Figure 5A). CQ-induced Rab8b expres-
sion, but not Rab8a expression, in wild-type MEFs (Figure 5A).
CQ also induced Rab8b in normal human cells (Figure S5B)
but not in cancer cells (Figure S5A). We confirmed that Rab8b
null MEF cells were not deficient in p53 induction in response
to CQ (Figure S5C). Moreover, we tested the effect of transiently
Figure 4. CQ Induced Par-4 Secretion by a
BFA-Sensitive, p53-Dependent Pathway
(A) CQ induced Par-4 secretion by a p53-depen-
dent mechanism. P53+/+ or p53/ MEFs were
treated with CQ (25 mM), Arylquin-1 (Aq 1; 500 nM),
Nutlin-3a (N; 10 mM), or vehicle (V) for 24 hr, and the
CM and lysates were examined by western blot
analysis with the indicated antibodies.
(B) CQ induced p53 activation. Wild-type (p53+/+)
or p53/ MEFs were treated with CQ (25 mM) or
vehicle (V) for 24 hr, and the CM and lysates were
examined by western blot analysis with the indi-
cated antibodies.
(C) CQ inhibited UACA expression. Wild-type
MEFs and p53/ MEFs (left panel) or HEL cells
(right panel) were treated with CQ (25 mM) or
vehicle (V) for 24 hr, and the CM and lysates were
examined by western blot analysis with the indi-
cated antibodies.
(D) CQ induced Par-4 secretion by a BFA-sensitive
mechanism. MEFs were pre-treated with BFA
(1 mg/mL) or vehicle for 30 min and further treated
with CQ (25 mM) or vehicle (V) for 4 hr. The CM and
lysates were examined by western blot analysis
with the indicated antibodies.
See also Figure S4.
transfecting Rab8b null MEFs with mouse
Rab8b expression construct or vector for
control and noted that CQ induced Par-4
secretion in Rab8b reconstituted cells
(Figure 5B). Knocking down Rab8b with
small interfering RNAs (siRNAs) resulted
in the inhibition of Par-4 secretion in
the CM, as judged by western blot anal-
ysis (Figure 5C), and the reintroduction
of GFP-Rab8b into MEFs, after knock-
down of endogenous Rab8b with siRNA
rescued Par-4 secretion (Figure 5D).
Theguardianof thegenomep53binds to
a consensus motif 50-PuPuPuC4(A/T)(A/T)
G7PyPyPy [0–13] PuPuPuC4(A/T)(A/T)G7PyPyPy-30 (where pu-
rines at positions 4 and 7 are critical) in the promoter of genes
that it transcriptionally regulates (el-Deiry et al., 1992). Puta-
tive p53-binding sites 50-GGGGCACGCCCGAGGCTCCCC-30
on human chromosome 15 (corresponding to nucleotides at
positions 63481874 to 63481894) and 50-GGAGAGCCG
CGGGCGTGCCT-30 on mouse chromosome 9 (corresponding
to nucleotides at positions 66767671 to 66767690) were noted in
the promoter regions upstreamof the transcription start site of hu-
man and mouse Rab8b, respectively (http://www.sabiosciences.
com/chipqpcrsearch.php). CQ enhanced Rab8b protein levels in
p53 wild-type cells, but not in p53 null cells, and quantitative
real-time PCR studies indicated that CQ induced Rab8b mRNA
in a p53-dependent manner (Figure 6A).
To determine whether p53 directly binds to this consensus-
binding motif within the Rab8b promoter in order to induce
Rab8b expression, we treated MEF cells with CQ or vehicle and
subjected the DNA to chromatin immunoprecipitation analysis
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with p53 antibody (Ab) or control IgG antibody. As seen in Fig-
ure 6B, relative to vehicle, treatment with CQ resulted in elevated
levels of chromatin immunoprecipitation of the p53-consensus
motif in Rab8b. By contrast, either the control IgG antibody used
along with primers near the p53-binding site in the Rab8b pro-
moter or the p53 antibody used alongwith primers corresponding
to the region in the GAPDH promoter or Par-4 gene, where p53
was not expected to bind, failed to show chromatin immunopre-
cipitation (Figure 6B). These findings indicated that p53 directly
bound toRab8band thatCQ treatment resulted in increased inter-
action of p53 with its binding motif in the Rab8b promoter.
We also performed an immunocytochemical (ICC) analysis to
determine the localization of Par-4 in Rab8b-coated vesicles.
Relative to vehicle treatment, CQ induced an increase in the
Figure 5. CQ Induced Par-4 Secretion Is Dependent on Rab8b
(A) CQ induced Par-4 secretion by a Rab8b-dependent mechanism. Rab8 wild-type (WT), Rab8b/, or Rab8a/ MEFs were treated with CQ (25 mM) or vehicle
(V) for 24 hr, and the CM or lysates were examined by western blot analysis with the indicated antibodies.
(B) Induction of Par-4 secretion in response to CQ in Rab8b null cells was restored by re-introduction of Rab8b. Rab8b null MEFswere transiently transfectedwith
GFP-mouse Rab8b (GFP-mRab8b) expression construct or GFP-expression construct for control, and the transfectants were treated with CQ (25 mM) or vehicle
for 24 hr. The CM and lysates from the cells were examined by western blot analysis with the indicated antibodies.
(C) Par-4 secretion in response to CQ was inhibited by Rab8b siRNAs. Wild-type MEFs were transfected with siRNA duplexes from two different sources,
Dharmacon (D) and Santa Cruz Biotechnology (SC), or with scrambled siRNA duplexes for control, and the transfectants were treated with CQ (25 mM) or vehicle
for 24 hr. The CM and lysates from the cells were examined by western blot analysis with the indicated antibodies.
(D) Introduction of human Rab8b in Rab8b-knockdown MEFs resulted in restoration of Par-4 secretion in response to CQ. MEFs were transfected with the
indicated siRNAs, 24 hr later, they were re-transfected with GFP-human Rab8b (GFP-hRab8b) or GFP expression construct, and the transfectants were treated
for 24 hr with CQ (25 mM) or vehicle. Western blot analysis of the CM and lysates was performed by using the indicated antibodies. Knockdown of endogenous
Rab8b was confirmed with the Rab8b antibody, and expression of GFP-hRab8b was detected with the GFP antibody.
See also Figure S5.
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co-localization of Par-4 with Rab8b-containing vesicles, and
BFA prevented Par-4 from entering the Rab8b vesicles (Figures
6C and S6). Together, these findings indicated that the Rab8b
gene was induced in a p53-dependent manner and that Rab8b
was essential for CQ-induced secretion of Par-4 by the BFA-sen-
sitive post-Golgi pathway to plasma membrane.
Figure 6. Rab8b Is a Direct Downstream Target of p53, which Is Activated by CQ
(A) CQ induced Rab8b protein and mRNA levels in a p53-dependent manner. Wild-type (p53+/+) or p53/ MEFs were treated with CQ (25 mM) or vehicle (V) for
24 hr; and either the lysates were examined by western blot analysis with the indicated antibodies (left panel), or mRNA prepared from the cells was examined by
real-time qRT-PCR (right panel). *p < 0.001, by Student’s t test.
(B) p53 directly bound to its consensus-binding site in theRab8b promoter. MEF cells were treated with CQ or vehicle (V) and subjected to ChIP analysis with p53
antibody (p53 Ab) or control IgG antibody, and immunoprecipitated DNA fragments were amplified and analyzed on agarose gels (left panel) or by real-time qPCR
(right panel) with primers near the p53-binding site in Rab8b promoter. The immunoprecipitated fragments were similarly analyzed with random primers for
GAPDH promoter or two different primer sets for the Par-4 gene, which does not contain a p53-binding site. *p < 0.001, by Student’s t test.
(C) Par-4 co-localized with Rab8b+ vesicles in CQ-treated cells. MEFs were treated with vehicle (V) or CQ (25 mM) in the absence or presence of BFA (1 mg/mL) for
24 hr and subjected to ICC analysis for Par-4 (red fluorescence) and Rab8b (red fluorescence). Cells were stained with DAPI to reveal their nuclei (blue fluo-
rescence). Co-localization of Par-4 and Rab8b vesicles in the overlay images is indicated by yellow fluorescence. Note the dissociation of Par-4 and Rab8b (loss
of yellow fluorescence but retention of red and green fluorescence) in the CQ+BFA panel. Cells showing co-localization of Rab8b and Par-4 were scored, and the
data are expressed as percentage of cells showing co-localization (right panel).
Error bars indicate mean of at least three independent experiments ± SD. See also Figure S6.
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DISCUSSION
An unbiased screen of FDA-approved quinoline- and quinolone-
containing drugs as Par-4 secretagogues led to the identification
of the anti-malarial drug CQ and its hydroxylated analog, HCQ,
as robust inducers of Par-4 secretion from normal cells. CQ
also induced p53 expression and required p53 for successful in-
duction of Par-4 secretion. Our studies indicated that p53
induced by CQ directly bound to the promoter of Rab8b and pro-
moted Par-4 secretion through the upregulation of Rab8b, a pre-
viously unknown target of p53. Importantly, Rab8b expression
was critical for Par-4 secretion. CQ-induced secretion of Par-4
was prevented by BFA, which blocked the conventional pathway
by inhibiting the post-Golgi transport of the protein cargo to the
plasmamembrane but which did not block the non-conventional
pathways (Klausner et al., 1992; Grieve and Rabouille, 2011).
Loss of Rab8a, which was necessary for autophagic secretion
(Dupont et al., 2011), did not prevent the induction of Par-4
secretion by CQ, and Par-4 secretion occurred independently
of the non-conventional, autophagic pathway. The physiological
relevance of the findings was immediately evident, because CQ
induced elevated levels of Par-4 secretion systemically in mice
and patients. These Par-4 levels were sufficient to induce para-
crine apoptosis of diverse p53-deficient cancer cells. It was
particularly noteworthy that CQ inhibited the growth of lung tu-
mor nodules in a Par-4-dependent manner. Collectively, CQ
induced tumor cell apoptosis and inhibition of lung tumor nod-
ules via a paracrine effect of Par-4 secreted from normal cells.
Because CQ showed encouraging results in clinical trials de-
signed to test the potential repurposing of CQ for cancer treat-
ment (Rebecca and Amaravadi, 2016), and because Par-4
induced apoptosis in a broad range of cancer cells, but not in
normal cells (Burikhanov et al., 2009), the tumor-growth-inhibi-
tory action of CQ was attributed to its ability to induce Par-4
secretion from normal cells.
Structural Similarities of CQ with Arylquin-1
CQ and Arylquin-1 shared a common pharmacophore—namely,
the heterocyclic quinoline ring—but they differed in two impor-
tant respects. First, they differ appreciably at the C-3 and C-4
positions, where CQ possessed a dibasic, 5-(N,N-diethyla-
mino)pentyl-2-amino subunit at C-4 and where Arylquin-1
possessed a non-basic, ortho-fluorophenyl subunit at C-3. A
second difference between these two secretagogues lies in the
presence of the C-7 chloro group in CQ and the C-7 N,N-dime-
thylamino group in Arylquin-1. The second difference between
CQ and Arylquin-1 appeared to be of less consequence than
the primary difference at C-3 and C-4. Although both agents pro-
moted Par-4 secretion, and both possessed a common quino-
line substructure, it would be premature to conclude that one
is a surrogate for the other, given the differences in basicity
and hydrophobicity at C-3 and C-4 that could alter their individ-
ual mechanisms of action.
CQ Induced p53 Activation and Par-4 Secretion
CQ blocked degradative autophagy at the final step of autopha-
gosome fusion with the lysosome and did not promote secretory
autophagy involving the inflammasome and Rab8a vesicles (Du-
pont et al., 2011). Our studies indicated that CQ induced the
accumulation of p62 and LC3II in normal cells. This finding
implied that CQ blocked the expected autophagy. However,
CQ has multiple modes of action in cells, and prior studies sug-
gested that CQ-induced activation of ATM results in activation
and elevated expression of p53 that, in turn, triggered the
apoptosis of selective cancer cells (Loehberg et al., 2007; Ma-
clean et al., 2008). In the present study, CQ showed activation
of p53 in normal cells; and, similar to our findings with Nutlin-
3a, which was structurally unrelated to CQ but also activated
p53 by inhibition of MDM2 (Burikhanov et al., 2014a), the growth
of normal cells was not inhibited following p53 activation by CQ.
On the contrary, CQ-induced activation of p53 stimulated normal
cells to secrete the cancer-selective, pro-apoptotic, Par-4 pro-
tein. The ability of p53 to induce the secretion of proteins repre-
sented a previously unrecognized function for p53 (Burikhanov
et al., 2014a; Yu et al., 2006). Unlike most proteins that lacked
a leader sequence and whose secretion was induced by p53
via the non-conventional, exosomal pathway (Yu et al., 2006),
p53 induced the secretion of Par-4 via the conventional secre-
tory pathway (Burikhanov et al., 2014a).
Although CQ was reported to activate multiple processes in
cells, p53-dependent induction of Par-4 secretion by CQ was
functionally linked to the ability of Par-4 to induce paracrine
apoptosis of cancer cells and inhibit the growth of lung tumor
nodules in mice. Accordingly, in response to CQ, p53 null cells
failed to secrete Par-4, and Par-4 null cells or Par-4 null mice
failed to show paracrine apoptosis or tumor growth inhibition,
respectively. It was interesting that CQ failed to induce robust
Par-4 secretion in a broad range of cancer cells. The inability
to secrete Par-4 was associated with the lack of p53 induction
by CQ. Thus, CQ selectively induced Par-4 secretion from
normal cells by a mechanism tightly linked to p53 activation.
The studies reported here, thus, uncovered a previously undis-
covered function of CQ to induce protein secretion via p53
activation.
CQ Induced Par-4 Secretion by Rab8b-Dependent
Mechanism
Although the transcription of proteins with diverse functions was
undoubtedly regulated by p53, the downstream mediators of
p53-dependent trafficking of proteins for secretion via the con-
ventional secretory pathway remained unclear at the outset of
this work. Our previous studies (Burikhanov et al., 2014a) indi-
cated that Nutlin-3a induced direct binding of p53 to the pro-
moter of the UACA gene at the consensus-binding motif and in-
hibited its expression. This binding event allowed the release of
Par-4, which was sequestered by UACA in the ER, for secretion.
The present study showed that CQ-induced Par-4 secretion
in normal cells was also associated with inhibition of NF-kB ac-
tivity and its downstream target UACA. By contrast, NF-kB activ-
ity and UACA expression were not inhibited by CQ in cancer
cells, and this blockade presumably prevented Par-4 secretion
from those cells in response to CQ. Unlike CQ and Nutlin-3a,
which inhibited UACA expression, Arylquin-1 did not inhibit
UACA (Figure S5D). As Arylquin-1 caused the release of Par-4
from vimentin for secretion (Burikhanov et al., 2014b), these find-
ings indicated that Par-4 secretagogues induced Par-4 secretion
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by either a UACA-suppression-dependent or a UACA-suppres-
sion-independent mechanism.
Although UACA downregulation was essential for Par-4 secre-
tion, it was not sufficient for Par-4 secretion in normal cells lack-
ing p53 function (Burikhanov et al., 2014a).We, therefore, sought
to identify other regulators of Par-4 secretion whose function
was dependent on p53. In particular, we focused on GTPase-
driven protein transport vesicles, because they were critical for
trafficking proteins from the Golgi to the plasma membrane.
These studies identified Rab8b as a critical mediator of Par-4
secretion by CQ. Although it was conceivable that p53 regulated
still other protein transporters along the conventional pathway,
our studies indicated that Rab8b met the key essential criteria
for Par-4 transport for secretion in response to CQ: (1) a p53-
bindingmotif was present in Rab8b, but not in the closely related
isoform Rab8a, and, accordingly, only Rab8b was induced by
CQ in a p53-dependent manner; (2) p53 directly bound to the
promoter of Rab8b at its consensus-binding motif; (3) Rab8b
null MEFs showed p53 induction in response to CQ but failed
to induce Par-4 secretion; (4) all the currently known Par-4 se-
cretagogues—namely, Nutlin-3a, Arylquin-1, and CQ—induced
Par-4 secretion by aRab8b-dependentmechanism (Figure S5E);
(5) Par-4 was expressed at the apical surface of luminal cells, as
seen, for instance, in the secretory epithelial cells of the prostate
(Boghaert et al., 1997), and Rab8b was essential for the apical
transport of proteins (Sato et al., 2014); (6) Par-4 co-localized
with Rab8b vesicles in normal cells, and co-localization was in-
hibited by BFA; and (7) cancer cells that failed to induce p53
and Rab8b expression also failed to show induction of Par-4
secretion in response to CQ. Collectively, these findings identi-
fied Rab8b as a target of p53 that was essential for Par-4 trans-
port from the Golgi to the plasma membrane via the BFA-sensi-
tive classical secretory pathway. Because Rab8b null cells failed
to induce Par-4 secretion in response to CQ, Rab8b was abso-
lutely necessary for CQ-induced Par-4 secretion. Studies are un-
derway to evaluate the significance of other Rabs in the action of
CQ and to determine whether the GTPase function of Rab8bwas
involved in the sorting of Par-4 into transport vesicles in the post-
Golgi trafficking that led to secretion.
Paracrine Apoptosis and the Tumor Growth Inhibitory
Action of CQ Were Dependent on Par-4
Previously known functions of CQ include autophagy regula-
tion, lysosomal destabilization, and normalization of tumor
vasculature. This study uncovered the ability of CQ to induce
the secretion of Par-4, a pro-apoptotic tumor suppressor from
normal cells. Both human and mouse fibroblasts and epithelial
cells of diverse origins showed Par-4 secretion, and Par-4
secretion was observed from normal mice, as well as from hu-
man renal cancer patients who were treated with CQ in a clin-
ical trial. Moreover, CQ-induced Par-4 secretion was sufficient
to effect the ex vivo apoptosis of cancer cells. CQ inhibited
the growth of lung tumor nodules in wild-type mice but not
in Par-4 null mice, an observation that implied that Par-4 func-
tion was critical for CQ-induced lung tumor growth inhibition.
Because our previous studies indicated that Par-4, when in-
jected in mice, inhibited the growth of lung tumors (Zhao
et al., 2011), and because the plasma of CQ-treated mice
induced ex vivo apoptosis by a Par-4-dependent mechanism,
Par-4 secretion induced in response to CQ was involved in
the experimental metastasis inhibitory effect of this FDA-
approved drug. CQ showed encouraging results in clinical trials
designed to re-purpose it as an anti-cancer drug, especially
in combination with standard-of-care therapy (Rebecca and
Amaravadi, 2016). The present findings indicated that the
mechanism of CQ action was not limited to its direct cytotoxic
action via autophagy inhibition and that Par-4 was a significant
contributor to the paracrine effects of CQ against metastatic
lung tumor growth.
In summary, this work identified the mechanism by which
CQ caused paracrine apoptosis and tumor growth inhibition.
This mechanism involved induction of Par-4 secretion by CQ
from normal cells at levels sufficient to cause the paracrine
apoptosis of cancer cells. Our studies revealed an unrecog-
nized role for Rab8b, a target of p53, in trafficking Par-4 for
secretion. Secretatogues such as CQ utilized p53 activation,
which, in turn, induced Rab8b for Par-4 transport via the
classical secretory pathway from the Golgi to the plasma
membrane for secretion. Thus, although p53 loss in tumors
often rendered them refractory to treatment, the relatively
safe, FDA-approved drug, CQ, empowered normal cells to
secrete Par-4 and induce apoptosis in tumor cells that lacked
p53 tumor suppressor function.
EXPERIMENTAL PROCEDURES
Cells and Plasmids
Human lung cancer cells A549, H460, H1299, and HOP92; mouse lung cancer
LLC1 cells; human prostate cancer cells LNCaP, DU145, and PC-3; and HELs,
HBECs, and BEAS-2B cells were from ATCC. C4-2B cells were from Leland
Chung (Cedars-Sinai Medical Center), and normal human PrSs and PrEs
were from Lonza. Mousemammary tumor cells EO771were a kind gift of Linda
Matheny-Barlow, Wake Forest Cancer Center, Winston-Salem, NC. KP7B
cells were from Tyler Jacks, MIT. Rab8b+/+, Rab8a/, and Rab8b/ MEFs
were derived from wild-type or knockout mice (Sato et al., 2014).
Antibodies and siRNA Duplexes
Par-4 (R334) for western blot and Par-4 (C-19, sc-1249 goat) for ICC analysis;
and GRP78 (N20), Col1A1 (H-197), LC3 (H-47), p21 (C-19), PIG3 (H-300),
c-IAP1 (H-83), XIAP (A-7), and pan-cytokeratin (C11) antibodies were from
Santa Cruz Biotechnology. UACA, Rab8b (ab124356, rabbit), and Rab8a
(ab188574, rabbit) antibodies were from Abcam. Active caspase-3 antibody
(Asp175) (5A1E), p62 antibody (Sequestosome-1, SQSTM1) (5114), and p53
antibody (1C12) were from Cell Signaling. The b-actin antibody was from
Sigma Chemical. Rab8b siRNA duplexes were from Dharmacon (D), and pools
of Rab8b siRNA and scrambled siRNA duplexes were from SantaCruz
Biotechnology (SC). Human GFP-tagged Rab8B (RG204651) and mouse
GFP-tagged Rab8b (MG202204) were from Origene Technologies.
Reporter Assays, Cell-Cycle Analysis, and Apoptosis Assays
Todetermine the effect of CQonp53-dependent transcription orNF-kB-depen-
dent transcription, cells were co-transfected with p53-response element-
luciferase reporter PG13-luc or mutant response element-luciferase reporter
MG15-luc (from Addgene) or with NF-kB-luciferase reporter construct, respec-
tively, or with minimal promoter-luciferase vector pGL3 as control, along with
b-galactoside construct, and then treated with CQ or vehicle. After 24 hr, cell
lysates were quantified for luciferase activity, which was normalized relative to
the corresponding b-galactoside activity, as described previously (Burikhanov
et al., 2009). Cell-cycle distribution was accessed using propidium iodide
staining of wild-type or p53 null MEFs treated with CQ or vehicle in a Becton
Dickinson LSRII flow cytometer.
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Apoptotic cells were identified by ICC analysis for active caspase-3, and
apoptotic nuclei were revealed by 4, 6-diamidino-2-phenylindole (DAPI) stain-
ing (Burikhanov et al., 2014b). A total of three independent experiments were
performed, and approximately 500 cells were scored in each experiment for
apoptosis under a fluorescent microscope.
Quantitative Real-Time RT-PCR Assay
Wild-type MEFs and p53 null MEFs were treated with either vehicle or CQ
(25 mM), and RNA was purified using the RNeasy Plus Kit (QIAGEN). First-
strand cDNA was prepared by reverse transcription using the iScript Select
cDNA Synthesis Kit (Bio-Rad), and qPCR was performed using the CFX96
Touch Real-Time PCR Detection System (Bio-Rad). Data were analyzed by
the delta delta Ct’ (DDCt) method, and Rab8b expression was quantified rela-
tive to GAPDH.
ChIP Assay
ChIP assays for CQ-induced or vehicle-treated basal levels of p53 binding to
the Rab8b promoter or to Par-4 gene are described in the Supplemental
Experimental Procedures.
Co-localization of Par-4 in Rab8b-Coated Vesicles
Cells in chamber slides were treated with CQ or vehicle in the presence or
absence of BFA and subjected to ICC analysis with Par-4 (C-19 goat) primary
antibody and donkey anti-goat secondary antibody conjugated to Alexa Fluor
568 (red fluorescence; A10042, Invitrogen) and with Rab8b (rabbit) primary
antibody and donkey anti-rabbit secondary antibody conjugated to Alexa
Fluor 488 (green fluorescence; A11055, Invitrogen). Cells were stained with
DAPI to reveal their nuclei (blue fluorescence).
Animal Experiments
All animal experiments are described in the Supplemental Experimental
Procedures.
Statistical Analysis
All experiments were performed in triplicate to verify the reproducibility of the
findings. The results show a mean of at least three experiments ± SD. Statis-
tical analyses were carried out with Statistical Analysis System software (SAS
Institute), and p values were calculated using the Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.12.051.
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